XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.

XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Oncol Rep. 2019 Jan 09;: Authors: Teng X, Fan XF, Li Q, Liu S, Wu DY, Wang SY, Shi Y, Dong M Abstract Xeroderma pigmentosum, complementation group C (XPC) is an accessory recognition gene involved in the nucleotide excision repair (NER) pathway, which is activated during the initial DNA damage recognition stage. It participates in the regulation of DNA damage‑induced proliferation and apoptosis. Emerging evidence demonstrates that upregulation of XPC increases the resistance of several tumor cell types to cytotoxic drugs. In addition, it can predict poor patient outcome for non‑small cell lung cancer (NSCLC). However, the mechanisms linking upregulation of XPC and drug resistance in lung cancer are still unclear. In the present study, we aimed to confirm whether XPC was involved in the reversal of the cisplatin (DDP) resistance in drug‑resistant A549/DDP lung adenocarcinoma cells. RT‑PCR and western blot assays were used to examine XPC mRNA and protein expression levels. Cell viability was assessed by CCK‑8 assay. The knockdown of XPC was achieved in A549/DDP cells using si‑RNA, whereas cell proliferation and apoptosis were assessed by wound healing assay and flow cytometric analysis, respectively. The median inhibitory concentration (IC50) value of DDP was assessed by CCK‑8 assay. Western blot assays were conducted for the ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Authors: Bai Y, Xiong L, Zhu M, Yang Z, Tang H, Zhao J Abstract Lung cancer is a malignant tumor with high morbidity and mortality, of which 80% is non-small cell lung cancer (NSCLC). And lung adenocarcinoma (LUAD) is the most important and common subtype in the NSCLC. In current study, the microarray data GSE31210 containing LUAD (n= 226) and normal lung tissue (n= 20) was analyzed to identify 965 differentially expressed genes, on which weighted gene co-expression network analysis was performed. Finally, it was confirmed that there was a significant correlation between brown module and LUAD stage. In the signific...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Activating mutations of the Epidermal Growth Factor Receptor (EGFRMUT) gene are found in approximately 10-12% of Caucasian patients affected by non small-cell lung cancer (NSCLC), with higher prevalence in adenocarcinoma histology, never smokers and females [1]. Exon 19 deletions and exon 21 L858R point mutation represent about 90% of these activating alterations [2]. For many years, first- (gefitinib and erlotinib) or second-generation (afatinib) EGFR-tyrosine kinase inhibitors (TKIs) have been considered the standard first-line therapy for patients with advanced EGFR-mutated NSCLC, based on the excellent outcome in compa...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionPrevious RT was an independent prognostic marker of favorable prognosis after nivolumab administration and improved the response rate to nivolumab treatment. Previous RT was clinically identified to have a synergistic effect with nivolumab treatment, increasing the response rate and improving the outcome of patients with advanced NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Zhu YC, Zhang XG, Lin XP, Wang WX, Li XF, Wu LX, Chen HF, Xu CW, Du KQ Abstract C-ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement forms a novel molecular subgroup of non-small cell lung cancer (NSCLC). The present study explored the clinicopathological features and clinical efficacy of crizotinib in patients with ROS1-positive NSCLC. A retrospective analysis of 2,617 cases of NSCLC diagnosed between January 2013 and December 2016 was performed. ROS1 fusion genes were detected by reverse transcription-quantitative polymerase chain reaction, fluorescence in situ hybridization or next-generation ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
AbstractA 69-year-old man with stage IIIB lung adenocarcinoma received durvalumab following chemoradiotherapy. The prescribed dose was 50  Gy in 2 Gy fractions, and the maximum spinal cord dose was 40 Gy. After three cycles of durvalumab, he experienced bladder and rectal disturbance, muscle weakness in the lower limbs, and sensory loss in the lower body. Magnetic resonance imaging revealed T2 signal hyperintensity involving the th oracic spinal cord. As the thoracic spinal cord with T2 signal hyperintensity matched with the irradiated site, the patient was diagnosed with radiation myelitis. This case report...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: : When used to treat LANSCLC in the neoadjuvant setting, both IMRT and 3DCRT produce comparable pathologic and clinical outcomes. ADVANCES IN KNOWLEDGE: : This study validates the real-world effectiveness of IMRT compared to 3DCRT. PMID: 30864828 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
Programmed Death Ligand 1(PD-L1) testing is recommended for patients with Non Small Cell Lung Cancer (NSCLC) at stage IIIB and IV, adenocarcinoma and squamous cell carcinoma. Up to now, no clinical-pathological parameters are perfectly able to select a positive PD-L1-patient. For this reason PD-L1 testing is mandatory for patients with advanced NSCLC for whom an immune checkpoint inhibitor treatment is appropriate. Several studies on the cost-effectiveness of immune checkpoint inhibitors in this subset of patients have been published [1 –3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, both low SUVmax and low NQO1 was an independent prognostic factor in SQCC alone. The sample size was small but there was a positive correlation between NQO1 expression and SUVmax in SQCC. PMID: 30868898 [PubMed - in process]
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research
CONCLUSIONS: Decorin inhibits invasion and metastasis of non-small cell lung cancer through the TGF-β signaling pathway. PMID: 30840274 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively. Their role in cancer immu...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study